Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederprnewswire.com
PR Newswire:
Get the latest updates from PR Newswire: directly as they happen.
Follow now 159 followers
Latest posts
Last updated about 2 hours ago
WANDA Week Celebrates 10 Years of Food Sheroes during Juneteenth
about 2 hours ago
WASHINGTON, June 14, 2026 /PRNewswire/ -- Women Advancing Nutrition, Dietetics, and Agriculture...
CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
about 3 hours ago
SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code...
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
about 3 hours ago
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen...
Die Menarini Group präsentiert auf dem Kongress der European Hematology Association (EHA) 2026 Daten aus der Phase-3-Studie SENTRY zur Kombination von Selinexor und Ruxolitinib bei Myelofibrose
about 10 hours ago
Die Kombination aus Selinexor und Ruxolitinib erreichte den ersten koprimären Endpunkt und...
Muscle Growth Supplements Featuring Magnesium, Ashwagandha and Omega-3s Are Highlighted by PureHealth Research
about 12 hours ago
MANASSAS, Va., June 14, 2026 /PRNewswire/ -- Strength, mobility, and recovery are...
Orbis International's Flying Eye Hospital Arrives in Peru to Expand Access to Essential Eye Care
about 13 hours ago
With support from Alcon, FedEx, and OMEGA, the Orbis Flying Eye Hospital...
SAMARITAN'S PURSE EBOLA TREATMENT CENTERS OPEN IN THE EPICENTER OF THE DEADLY OUTBREAK
about 14 hours ago
BOONE, N.C., June 14, 2026 /PRNewswire/ -- Samaritan's Purse has established two...
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
about 16 hours ago
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating...
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
about 20 hours ago
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over...
Marler Clark Urges Parents to Stop Using Nara Organics Whole Milk Organic Powdered Infant Formula Amid Multistate Infant Botulism Outbreak -- Product Sold Nationwide at Target
1 day ago
FDA, CDC, and public health officials in California, Pennsylvania, and Washington are...
Simcere Pharmaceutical schließt eine Forschungskooperationsvereinbarung mit Stanford Medicine zur Entwicklung innovativer Therapien für Patienten mit idiopathischer Lungenfibrose
1 day ago
SHANGHAI, 13. Juni 2026 /PRNewswire/ -- Am 29. Mai 2026 (Pacific Time)...
Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million
1 day ago
NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology...